

DRUG PRIOR AUTHORIZATION COMMITTEE

March 18, 2010
TENTATIVE AGENDA

10:00 - 10:05	Welcome, Announcements and Introductions	Henry Petry, Chairman
10:05 - 10:15	Minutes Review	Discussion/ Approval
10:15- 11:30	Pharmacy Program/ Budget Update PDL Process Discussion	George L. Oestreich/ Andrew Haslag
11:30 - 11:35	DUR Update	Tisha McGowan
	<u>Old Business</u>	
11:35 - 12:05	a. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Rhonda Driver Jay Bryant Wimp
	<u>New Business</u>	
12:05 – 12:20	New Drug/Product Reviews	
	a. Proposed Actions (See website and Attached Summary)	Rhonda Driver Jay Bryant Wimp
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. PDL Products	
	iv. Prior Authorization	
12:20-1:45	<i>Proposed New Program Actions of Existing Products</i>	Rhonda Driver Jay Bryant Wimp
	a. <u>Drug List (PDL)</u>	
	i. Antiemetics-Oral	
	• Discussion	
	• Public Hearing	
	• Decision	
	ii. Beta Adrenergic Agents-Long Acting	
	• Discussion	
	• Public Hearing	
	• Decision	
	iii. Beta Adrenergic Agents-Nebulized	
	• Discussion	
	• Public Hearing	
	• Decision	
	iv. Beta Adrenergic Agents-Short Acting	
	• Discussion	
	• Public Hearing	
	• Decision	
	v. COPD Anticholinergics	
	• Discussion	
	• Public Hearing	
	• Decision	
	vi. Hematopoietic Agents	
	• Discussion	
	• Public Hearing	
	• Decision	
	vii. Inhaled Corticosteroids	
	• Discussion	
	• Public Hearing	
	• Decision	
	viii. Insulins	
	• Discussion	
	• Public Hearing	
	• Decision	
	ix. Long Acting Insulins	
	• Discussion	
	• Public Hearing	
	• Decision	

- x. **Rapid Acting Insulins**
 - Discussion
 - Public Hearing
 - Decision
 - xi. **Insulin-Mix**
 - Discussion
 - Public Hearing
 - Decision
 - xii. **Ophthalmic NSAIDS**
 - Discussion
 - Public Hearing
 - Decision
 - xiii. **Sedative Hypnotics**
 - Discussion
 - Public Hearing
 - Decision
 - xiv. **Statins**
 - Discussion
 - Public Hearing
 - Decision
 - xv. **Triglyceride Lowering Agents**
 - Discussion
 - Public Hearing
 - Decision
 - xvi. **Urinary Tract Antispasmodics**
 - Discussion
 - Public Hearing
 - Decision
 - xvii. **Growth Hormones**
 - Discussion
 - Public Hearing
 - Decision
 - xviii. **Androgen Hormone Inhibitors**
 - Discussion
 - Public Hearing
 - Decision
 - xix. **Non-Ergot Dopamine Receptor Agonists**
 - Discussion
 - Public Hearing
 - Decision
 - xx. **Low Molecular Weight Heparins**
 - Discussion
 - Public Hearing
 - Decision
 - xxi. **Skeletal Muscle Relaxants**
 - Discussion
 - Public Hearing
 - Decision
 - xxii. **Benzoyl Peroxide/Clindamycin Topical Agents**
 - Discussion
 - Public Hearing
 - Decision
 - xxiii. **Platelet Inhibitor Agents**
 - Discussion
 - Public Hearing
 - Decision
- c. **Preferred Drug List**
- i. Process discussion
 - ii. Therapeutic classes-to be *announced at meeting*

1:45

LUNCH

2:00-2:20

Program Utilization Information

Rhonda Driver

2:20-2:30

Other Business

- i. *Top 25" Drugs by Cost*
- ii. *Clinical Edit Summary Report*
- iii. *Call Center Statistics*

*Informal comments will be accepted from members of the audience at various points in the agenda.
Times noted are approximate, Agenda may move more quickly*

Executive Session

2:30-2:35	Minutes Review	Discussion/Approval
2:35-3:00	Case Reviews	Rhonda Driver

NEXT MEETING: June 17, 2010 – 205 Jefferson Street, 10th Floor